Birabresib (OTX015)

For research use only. Not for use in humans.

目录号:S7360 别名: MK 8628 中文名称:比拉瑞塞

Birabresib (OTX015) Chemical Structure

CAS No. 202590-98-5

Birabresib (OTX015, MK 8628) 是一种有效的BET bromodomain抑制剂,在无细胞试验中对BRD2,BRD3,和BRD4的EC50范围为10 到 19 nM。Birabresib 可抑制 Nuclear receptor binding SET domain protein 3 (NSD3) 的靶基因表达。

规格 价格 库存 购买数量  
RMB 807.95 现货
RMB 3667.54 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Birabresib (OTX015)发表文献51篇:

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述 Birabresib (OTX015, MK 8628) 是一种有效的BET bromodomain抑制剂,在无细胞试验中对BRD2,BRD3,和BRD4的EC50范围为10 到 19 nM。Birabresib 可抑制 Nuclear receptor binding SET domain protein 3 (NSD3) 的靶基因表达。
特性 口服生物可利用的BRD2/3/4选择性抑制剂,处于临床I期临床试验,用于治疗血液学恶性肿瘤。
靶点
BRDs [1]
(Cell-free assay)
10-19 nM(EC50)
体外研究

OTX015抑制BRD2,BRD3,和BRD4与AcH4的结合,IC50的范围为92到112 nM,并抑制各种人癌细胞系的生长,GI50的范围为60到200 nM。[1] OTX015导致c-MYC表达快速下调,并且在ALKpos ALCL细胞系中,表现出与ALK抑制剂结合的协同抗增殖作用。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Rosetta2 DE3 NUT3eGZuTnWwY4Tpc44h[XO|YYm= NV35eJJTOzBibXnudy=> NEXkTlhFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEN{BDTDJiKEOwOkB1dyB2MUegZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2l;MD6wNFTPxE1w NXf1dZdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3 M4jSV2Z2dmO2aX;uJIF{e2G7 MWGzNEBucW6| NGfseoZFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLENkBDTDJiKEO0PUB1dyB2NkCgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2l;MD6wNFU1|ryPLh?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3 NW\ublN6TnWwY4Tpc44h[XO|YYm= M2\acVMxKG2rboO= NFTSfoxFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEOEBDTDJiKEOzN{B1dyB2NkCgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2l;MD6wNFbPxE1w NH7tO449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
MM1S M4nnemFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWfHb4FnPzJiaILz MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2PMWOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igc5IhW1KEIHHzd4F6NCCLQ{WwQVAvODB4M988UU4> NWjoRYJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G0PVAxPzBpPkOxOFkxODdyPD;hQi=>
Rosetta2 DE3 NEXvfZRHfW6ldHnvckBie3OjeR?= NFTm[5g{OCCvaX7z MlfwSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKUREOgRmQyKCh{NDD0c{AyPDRiYX3pco8h[WOrZDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hWm:|ZYT0ZVIhTEV|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4k:OC5yMUC3{txONg>? MofqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3 MlvWSpVv[3Srb36gZZN{[Xl? MoSwN|AhdWmwcx?= M3rFZ2Rqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlS0JGJFOSBqNESgeI8hOTZ6IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGtqRTBwMEGwPe69VS5? M3W3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3 NVHy[mlGTnWwY4Tpc44h[XO|YYm= M{nmWlMxKG2rboO= M{TYc2Rqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSyJGJFOSBqN{KgeI8hOjB3IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGtqRTBwMEG2Ou69VS5? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3 MnL1SpVv[3Srb36gZZN{[Xl? MlriN|AhdWmwcx?= MmDxSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKURESgRmQzKCh|M{OgeI8hPDZyIHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD6wNVY3|ryPLh?= M1PTR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
MV4-11 M3z4[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHe2T2I1KGSjeYO= M4\RN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IFPDT|gh[XO|YYmsJGlEPTB;MD6wNVc3|ryPLh?= NF[w[Go9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS2NVY5QCd-M{G0OlE3QDh:L3G+
MM1S MonLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYntRlFGPCCmYYnz MnfORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPTUHTJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPCCmYYnzJIJ6KEOFS{igZZN{[XluIFnDOVA:OC5yMkK3{txONg>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR4MU[4PEc,OzF2NkG2PFg9N2F-
Rosetta2 DE3 Mon5SpVv[3Srb36gZZN{[Xl? MWGzNEBucW6| NUDjfJJjTGm|cHzhZ4Vu\W62IH;mJGZCVS2uYXLlcIVlKFqEQUK0PEBnem:vIFLSSFQhSkRzIDi0OEB1dyBzNkigZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3ME2wMlAzPTYQvF2u MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
THP1 M3K1dmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NV73d21qSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUTHAyKGOnbHzzMEBKSzVyPUCuNFM{|ryPLh?= M4\QNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUO5NVIyLz5{OEmzPVEzOTxxYU6=
BL21(DE3) MULGeY5kfGmxbjDhd5NigQ>? M2fnU|QhcHK| M2LrWGRqe3CuYXPlcYVvfCCxZjC1MWZKXENibHHi[Yxt\WRiKDupMWpSOSCocn;tJGhqezZvdHHn[4VlKGi3bXHuJGJTTDRiYoLvcY9ld22jaX6gNUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxLGRGOyliKT3jc4RwdiCybIXzMXJKVCClZXzsd{BqdmO3YnH0[YQh\m:{IESgbJJ{KGmwIHThdosh[2:wZHn0bY9vKGK7IH\seY9z\XOlZX7j[UBidmm|b4Tyc5B6KGKrbnTpcoch[XO|YYmsJGlEPTB;MD6wN|Q{|ryPLh?= M4jFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNEmwNFcxLz5|MUS5NFA4ODxxYU6=
MV4-11 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVu1VVB2PzJiaILz MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JGNmdGy2aYTy[U1odG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR|UxRTBwMES2N:69VS5? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjJyOE[wNEc,OzJ{MEi2NFA9N2F-
TY82 M2XnXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFK0PYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTZPFIh[2WubIOsJGlEPTB;MD6wOlfPxE1w NIi1[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmzPVEzOSd-Mki5N|kyOjF:L3G+
insect cells M3PjVGZ2dmO2aX;uJIF{e2G7 M173fGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdCCuZX7neIghcHWvYX6gUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCEUlS0JEgzKHSxIEGzOlIhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNidYPpcochcGm|dH;u[UBJPCCyZYD0bYRmKGG|IIP1ZpN1emG2ZTDifUBidHCqYTDzZ5Jm\W5iYYPzZZktKEmFNUC9NE4xQTMQvF2u MkjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3Mkm1OFYoRjNyNUK5OVQ3RC:jPh?=
LNCAP MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NF3jeldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzMEBKSzVyPUCuNVEyPM7:TT6= NEjJToY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
Kasumi-1 Ml30RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYe3NkBpenN? NF:4e3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvhd5VucS1zIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliQ3XscJRqfHKnLXfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4yOzYQvF2u NFH2OYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MkKwPFYxOCd-M{KyNFg3ODB:L3G+
MM1S MoCxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXnOb|VbPzJiaILz NFHCb5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3NNXMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBE\WyudHn0doUu\2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OD1yLkGzO:69VS5? NXnMXYd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KyNFg3ODBpPkOyNlA5PjByPD;hQi=>
RS4:11 MnPqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MkD4O|IhcHK| MnjoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUU{S6NVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBE\WyudHn0doUu\2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OD1yLkSxOu69VS5? NX;mbFBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KyNFg3ODBpPkOyNlA5PjByPD;hQi=>
MV4-11 MXXD[YxtKGO7Y3zlJIF{e2G7 MWWxNlUhdk1? M4qxTVI1KGi{cx?= NWDPfIFGS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVVZ2LUGxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGlY4XteYxifGmxbjDheEBIOS2yaHHz[UBifCBzMkWgcm0hdWWjc4Xy[YQh[W[2ZYKgNlQhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpk> Mnn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ{MEi2NFAoRjN{MkC4OlAxRC:jPh?=
MV4-11 M{PMXWZ2dmO2aX;uJIF{e2G7 M37kTVUxOCCwTR?= NIrZW3c3KHSxIEK0JIhzew>? NEfPNIlKdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hVVZ2LUGxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IEWwNEBvVSCvZXHzeZJm\CCjZoTldkA3KHSxIEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M2XuZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{MkC4OlAxLz5|MkKwPFYxODxxYU6=
MV4-11 NESxVmNHfW6ldHnvckBie3OjeR?= M2q0bVMyNjJ3IITvJFEzPSCwTR?= M{fISlYhcHK| NVXLO2J{UW6qaXLpeIlwdiCxZjDCVmQ1KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYz3NfYMhdVKQQTDs[ZZmdCCjdDCzNU4zPSC2bzCxNlUhdk1ibXXhd5Vz\WRiYX\0[ZIhPiCqcoOgZpkhW1mEUjDndoVmdiCmeXWgZoF{\WRiUmStdXBEWiCjbnHsfZNqew>? M2D5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{MkC4OlAxLz5|MkKwPFYxODxxYU6=
MV4-11 NYCxWmRSTnWwY4Tpc44h[XO|YYm= NY\JTppGOzFwMkWgeI8hOTJ3IH7N MXi2JIhzew>? NGPzNVRKdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hVVZ2LUGxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCEQ1yyJI1TVkFibHX2[Ywh[XRiM{GuNlUhfG9iMUK1JI5OKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHN[SlJiZ4Ll[Y4h\HmnIHLhd4VlKFKWLYHQR3Ih[W6jbInzbZM> M3r1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{MkC4OlAxLz5|MkKwPFYxODxxYU6=
MV4-11 MmrhSpVv[3Srb36gZZN{[Xl? NVrEdoZWOzFwMkWgeI8hOTJ3IH7N NWfib5QyPiCqcoO= MWfJcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBETEt4IH3SUmEhdGW4ZXygZZQhOzFwMkWgeI8hOTJ3IH7NJI1m[XO3cnXkJIFnfGW{IE[gbJJ{KGK7IGPZRnIh\3KnZX6g[JlmKGKjc3XkJHJVNXGSQ2KgZY5idHm|aYO= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjJyOE[wNEc,OzJ{MEi2NFA9N2F-
TY82 MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHHBNmU4OiCqcoO= MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFS\OEKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igc5IhW1KEIHHzd4F6 NGj1dpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5NFA4OCd-M{G0PVAxPzB:L3G+
MV4-11 NGTEUo1HfW6ldHnvckBie3OjeR?= MWqxNEB1dyBzMECgcm0> MmnRNlQhcHK| M2TuZWlvcGmkaYTpc44hd2ZiQmLEOEBqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGNvTYnjJI1TVkFibHX2[Ywh[XRiMUCgeI8hOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDy[YFtKHSrbXWgdXBEWiCjbnHsfZNqew>? NIrSeFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5NFA4OCd-M{G0PVAxPzB:L3G+
MV4-11 NFG0WZlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVu3NkBpenN? Ml:1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT|ghd3JiU2LCJIF{e2G7 M{jyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNEmwNFcxLz5|MUS5NFA4ODxxYU6=
MV4-11 MWPBdI9xfG:|aYOgZZN{[Xl? NYCzT4tMOjRiaILz M1rzTWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[gd5RicW6rbnegZoF{\WRiYYPzZZk> NI[2XW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5NFA4OCd-M{G0PVAxPzB:L3G+
RKO MXjD[YxtKGO7Y3zlJIF{e2G7 M4q4UFExOCCwTR?= NE\UbJAzPCCqcoO= NHK3VG1KdmS3Y4Tpc44hd2ZiY3XscEBkgWOuZTDhdpJme3RiaX6gbJVu[W5iUlvPJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGlY4XteYxifGmxbjDheEBIOSCyaHHz[UBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR7MEC3NEc,OzF2OUCwO|A9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
BRD4; 

PubMed: 26051217     


Small molecule BRD4 inhibitors lead to significant BRD4 accumulation. Namalwa and Ramos cells were treated overnight with increasing doses of JQ1 and OTX015. Lysates were collected and subjected to immunoblot analysis with antibodies for BRD4 and actin.

c-Myc; 

PubMed: 26051217     


Small molecule BRD4 inhibitors lead to downstream c-MYC suppression, but not efficiently. Namalwa cells were treated overnight with increasing doses of JQ1 and OTX015, lysates were collected and analyzed by immunoblot with antibodies for c-MYC and actin.

JAK2 / p-STAT5 / STAT5 / p-STAT3 / c-Myc / PIM1 / CDK6 / HEXIM1 / p27 / p21 / Bcl-xL / γH2AX; 

PubMed: 28042144     


SET-2 cells were treated with the indicated concentrations of ARV-825 or OTX015 for 18 hours. Total cell lysates were prepared and immunoblot analyses were conducted as indicated. The expression levels of β-Actin in the cell lysates served as the loading 䲧疝Ỵ疞

ZO-1 / Vimentin; 

PubMed: 27980063     


JQ1/OTX015 treatment results in decreased expression of the epithelial marker ZO-1 and an increase in mesenchymal marker Vimentin as shown by Western blot analyses of whole cell protein lysates.

26051217 28042144 27980063
Immunofluorescence
BRD4 ; 

PubMed: 28042144     


SET2 cells were treated with the indicated concentrations of ARV-825 or OTX015 for 16 hours. Then, cells were cytospun onto glass slides and immunostained for BRD4 expression. Cells were counterstained with DAPI and images were acquired utilizing confocal䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

Vimentin; 

PubMed: 27980063     


Immunofluorescence staining of Vimentin following JQ1/OTX015 treatment confirms a decreased epithelial phenotype.

28042144 27980063
体内研究 OTX015(口服)显著抑制Ty82 BRD-NUT中线癌肿瘤在裸鼠体内的生长,100 毫克/千克qd下能够抑制79%,10毫克/千克下抑制61%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

TR-FRET 试验[1]:

为了评估OTX015与BRD2,BRD3,以及BRD4的结合,BRD表达的CHO细胞裂解物(来自感染表达质粒的CHO细胞, Flag标记的BRD2,BRD3,或BRD4 或仅载体),铕共轭的抗Flag抗体,XL-665共轭的链霉亲和素,和生物素化的OTX015在室温下培育0.2到2小时。荧光性通过TR-FRET使用EnVision 2103多标阅读器测量,结合的EC50使用5.02版PRISM通过非线性回归计算。
细胞实验:

[1]

- 合并
  • Cell lines: 人肿瘤细胞
  • Concentrations: ~2 μM
  • Incubation Time: 72小时
  • Method:

    OTX015对癌细胞增殖的作用通过将人肿瘤细胞在逐渐增加浓度的OTX015下培育72小时进行评估,并使用基于四唑盐(WST-8)的比色测定评估。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: Ty82 BRD-NUT 中线肿瘤异种移植的BLAB/c-nu/nu小鼠。
  • Dosages: ~100 毫克/千克
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (199.19 mM)
Water Insoluble
Ethanol ''98 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 491.99
化学式

C25H22ClN5O2S

CAS号 202590-98-5
储存条件 粉状
溶于溶剂
别名 MK 8628

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01713582 Completed Drug: OTX015/Birabresib Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma Oncoethix GmbH December 14 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Epigenetic Reader Domain Signaling Pathway Map

Tags: 购买Birabresib (OTX015) | Birabresib (OTX015)供应商 | 采购Birabresib (OTX015) | Birabresib (OTX015)价格 | Birabresib (OTX015)生产 | 订购Birabresib (OTX015) | Birabresib (OTX015)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID